Tempus AI saw a welcome improvement to its Relative Strength (RS) Rating on Friday, with an upgrade from 80 to 88.
IBD's proprietary RS Rating measures market leadership by showing how a stock's price movement over the last 52 weeks compares to that of other stocks on the major indexes.
Decades of market research shows that the best stocks typically have an RS Rating of above 80 as they launch their biggest runs.
Hone Your Stock-Picking Skills By Focusing On These Factors
While Tempus AI is not near a proper entry right now, see if it goes on to form and break out from a proper base.
The company reported 0% EPS growth in the latest quarterly report, while sales growth came in at 33%.
The company earns the No. 14 rank among its peers in the Medical-Research Equipment/Services industry group. Veracyte, Natera and Medpace Holdings are among the top 5 highly rated stocks within the group.
RELATED:
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
